

# numit.


LIDOCAINE (LIGNOCAINE) 2.5% W/W PRILOCAINE 2.5% W/W

## NUMBING POWER THAT ENDURES<sup>^</sup>

<sup>^</sup>Following the application of numit cream for 1-2 hours, the duration of anaesthesia is at least 2 hours after removal of the occlusive dressing.



**#1**  
**NUMBING CREAM**  
IN PHARMACY<sup>6</sup>



## Dual-active anaesthesia


**Lidocaine (Lignocaine) 2.5% w/w Prilocaine 2.5% w/w combination cream can anaesthetise the full skin thickness – over 4mm deep.<sup>1,2</sup>**

Having the two anaesthetics in liquid form provides enhanced skin penetration in comparison to each component in crystalline form applied separately as a 2.5% topical cream.<sup>3</sup>

The anaesthetic cream forms a reservoir in the skin during occlusion that continues to be released after the cream is removed.<sup>4</sup>

Lidocaine 2.5% w/w Prilocaine 2.5% w/w combination cream utilised in these studies was not the Ego Numit brand.

## Numbing power that endures<sup>†</sup>



<sup>a</sup>Lidocaine (Lignocaine) 2.5% w/w and Prilocaine 2.5% w/w combination

<sup>b</sup>Statistically significant increase from baseline at all timepoints (n=12)

<sup>†</sup>Lidocaine (Lignocaine) 2.5% w/w Prilocaine 2.5% w/w combination cream has been shown to provide effective anaesthesia for

# 2 TO 4 HRS.<sup>2</sup>

The Lidocaine 2.5% w/w Prilocaine 2.5% w/w combination cream utilised in these studies was not the Ego Numit brand.

# numit.

For adult and paediatric use.

numit is indicated for topical anaesthesia of the skin prior to:<sup>5</sup>



Superficial surgical procedures



Injections

# Help to manage pain with the three C's – Coat, Cover, Clean.



FOLLOW THE DIRECTIONS FOR USE AS OUTLINED IN THE PRODUCT INFORMATION

## Can be used in adults, children, infants and neonates\*

\*Not suitable for premature infants. See product information for instructions for pediatric use.

### Instructions for use in adults



#### Small areas

For needle insertion or surgical treatment of localised lesions

Apply **1.5g to 2.0g** over **10cm<sup>2</sup>** of skin for a minimum of **1 hour** and a maximum of **5 hours**‡



#### Larger areas

Dermal procedures in a hospital setting (e.g. split-skin grafting)

Approx. **1.5g/10cm<sup>2</sup>**.  
Up to **2g** for a minimum of **2 hours** and a maximum **5 hours**‡

For superficial surgical and cosmetic procedures on larger areas

Use maximum of **60g** over **600cm<sup>2</sup>** of skin for a minimum of **1 hour** and a maximum of **5 hours**‡

Please review the complete instructions for use in each age group. Care should be taken in pregnant or breastfeeding women. Numit must not be applied to damaged or diseased skin without the advice of a doctor.

‡After a longer application time the anaesthesia decreases.

## Contact your supplier to order **numit.** today

Before recommending, please review the full Product Information, available on request from Ego Pharmaceuticals.

**References:** **1.** NIH. National Cancer Institutes SEER training modules [internet]. 2018 [cited 2018 May 1]. Available from <https://training.seer.cancer.gov/melanoma/anatomy/layers.html> **2.** Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of Emla cream. Br J Anaesth 1990; 64(2):173–7. **3.** US FDA. EMLA® CREAM (lidocaine 2.5% and prilocaine 2.5%). **4.** Tadicherla S, Berman B. Percutaneous dermal drug delivery for local pain control. Ther Clin Risk Manag 2006; 2(1):99-113. **5.** Numit Product Information. July 2019. **6.** IQVIA, Number 1 Numbing Cream in the TOPICAL ANAESTHETICS category, Australia Pharmacy Value Sales, September 2022 MAT data.

